Ophthalmological preparations

Similar documents
PRODUCT INFORMATION. 2-(dimethylamino) ethyl (RS)-2-(1-hydroxycyclopentyl)-2- phenylacetate hydrochloride

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

BETAGAN Allergan Levobunolol HCl Glaucoma Therapy

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

D90 (27/10/2005) Final SmPC NL/H/653/01

INDICATIONS For steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye globe.

INDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.

MINIMS AMETHOCAINE EYE DROPS

New Zealand Data Sheet

OCULAR PHARMACOLOGY GLAUCOMA. increased intraocular pressure. normally mm Hg. when to Tx no fixed level.

PRODUCT INFORMATION. Bis[(1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2RS)-3- hydroxy-2-phenylpropanoate] sulfate monohydrate

PRESCRIBING INFORMATION MYDFRIN * Phenylephrine Hydrochloride Ophthalmic Solution. Vasoconstrictor and Mydriatic for Use in Ophthalmology

LOWPROST Eye Drops (Bimatoprost Ophthalmic Solution 0.01%)

SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM

KEY MESSAGES. Details of the evidence supporting these recommendations can be found in the above CPG, available on the following websites:

PHARMACOLOGY Class: Ketorolac trometamol is a member of the pyrrolo-pyrolle group of non-steroidal antiinflammatory

SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM

8 USE IN SPECIFIC POPULATIONS Patients with Open-Angle Glaucoma or Ocular Hypertension

PRED-G (gentamicin and prednisolone acetate ophthalmic ointment, USP) 0.3%/0.6% sterile

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

MINIMS OXYBUPROCAINE EYE DROPS

Differential diagnosis of the red eye. Carol Slight Nurse Practitioner Ophthalmology

Dr Jo-Anne Pon. Dr Sean Every. 8:30-9:25 WS #70: Eye Essentials for GPs 9:35-10:30 WS #80: Eye Essentials for GPs (Repeated)

NEW ZEALAND DATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PRODUCT INFORMATION MINIMS OXYBUPROCAINE EYE DROPS NAME OF THE MEDICINE. Oxybuprocaine (benoxinate) hydrochloride. Chemical Structure

VI.2.2 Summary of treatment benefits

PRESCRIBING INFORMATION AND CONSUMER INFORMATION ISOPTO * CARPINE. pilocarpine hydrochloride ophthalmic solution, USP.

New Zealand Data Sheet

Proposed PIL NL/H/0653/001/IB/024/G. MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution in single-dose container Dexamethasone phosphate

Elements for a public summary. VI.2.1 Overview of disease epidemiology

Antiallergics and drugs used in anaphylaxis

INDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

MAXITROL* Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment, USP 3.5 mg (as neomycin sulfate), 6000 IU/g, 0.

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

APPROVED PACKAGE INSERT FOR XALATAN EYE DROPS. Each millilitre contains latanoprost 50 µg and benzalkonium chloride 0,02 % m/v as preservative.

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.

For a full list of excipients, see section 6.1. A sterile, clear, bright, colourless, aqueous solution.

a.superficial (adenoid layer).contain lymphoid tissue.

New Zealand Data Sheet

AUSTRALIAN PRODUCT INFORMATION ACULAR (ketorolac trometamol) Eye Drops

BNF/BNFC Chapter 11 Eye

PRECISION PROGRAM. Injection Technique Quick-Reference Guide. Companion booklet for the Video Guide to Injection Technique

Chemical Names: Prednisolone acetate: 11ß,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetate.

Acute Eyes for ED. Enis Kocak. The Alfred Ophthalmology

Brimonidine/timolol Version 1.2, 16Oct, Elements for a public summary. VI.2.1 Overview of disease epidemiology

ISOPTO HOMATROPINE Homatropine hydrobromide eye drops 2.0%

TOBAFLAM Eye Drops (Loteprednol etabonate 0.5% + Tobramycin 0.3%)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

NEW ZEALAND DATA SHEET

9 PM Eye Drops (Latanoprost 0.005%)

BRIMOPRESS-T EYE DROPS. COMPOSITION Each ml of BRIMOPRESS-T EYE DROPS contains. Brimonidine Tartarate 0.2% Timolol Maleate 0.5%

Neomycin B (R 1 =H, R 2 =CH 2 NH 2 ) Neomycin C (R 1 =CH 2 NH 2, R 2 =H) The chemical structure for the active ingredient Polymyxin B Sulfate is:

AUSTRALIAN PRODUCT INFORMATION FLAREX (FLUOROMETHOLONE ACETATE) EYE DROPS SUSPENSION

An Injector s Guide to OZURDEX (dexamethasone intravitreal implant) 0.7 mg

Medical Treatment in Pediatric Glaucoma

Condition: Herpes Simplex Keratitis

Primary Angle Closure Glaucoma

IOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose)

PRODUCT INFORMATION ALCAINE. Proparacaine Hydrochloride Sterile Ophthalmic Solution, USP. 5 mg/ml. Topical Anesthetic

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% (Sterile) Rx only

NAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.

GLAUCOMA. An Overview

PRODUCT INFORMATION. TRUSOPT eye drops

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

Drugs used in obstetrics

HIDROKORTIZON SA HLORAMFENIKOLOM (10 mg + 2 mg) / ml, eye drops, suspension

PRODUCT INFORMATION. PREDNEFRIN FORTE Eye Drops NAME OF THE MEDICINE

This leaflet's format was set and its contents inspected and approved by the Ministry of Health

Master SPC * Edition 05/2006 * (corresponds to German SPC, edition 03/2005)

THE RED EYE Cynthia McNamara, MD Week 25

ALCAINE Eye Drops contain proxymetacaine hydrochloride. The chemical structure of proxymetacaine hydrochloride is:

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination

CORNEAL CONDITIONS CORNEAL TRANSPLANTATION

PRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. IOPIDINE (apraclonidine hydrochloride) Eye Drops 0.5%

PRESCRIBING INFORMATION ISOPTO ATROPINE. Atropine Sulfate Ophthalmic Solution, BP. 1% w/v. Sterile. Cycloplegic - Mydriatic

CYCLOGYL * PRESCRIBING INFORMATION. Cyclopentolate Hydrochloride Ophthalmic Solution, USP. 1% w/v. Sterile. Anticholinergic

Trifluridine Ophthalmic Solution, 1% Sterile

Page 1 RED EYES. conjunctivitis keratitis episcleritis / scleritis. Frank Larkin Moorfields Eye Hospital. acute glaucoma anterior uveitis

Prescribing Information

OPHTHALMOLOGIC PEARLS FOR THE NON- OPHTHALMOLOGIST. David G. Gross D.O. Deen-Gross Eye Centers Merrillville-Hobart Deengrosseye.

SCHEDULING STATUS Schedule 4. PROPRIETARY NAME (AND DOSAGE FORM) GANFORT Eye Drops

KPA PFIZER EDUCATION GRANT

GATIQUIN-P Eye Drops (Gatifloxacin 0.3% + Prednisolone acetate 1%)

OPHTHALMOLOGY REFERRAL GUIDE FOR GPS

SUMMARY OF PRODUCT CHARACTERISTICS. Each ml contains 20 mg dorzolamide (as 22.3 mg of dorzolamide hydrochloride).

Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:

VIROPTIC Ophthalmic Solution, 1% Sterile (trifluridine ophthalmic solution)

Index. C Canalicular system, 4 Carbonic anhydrase inhibitors, 29 30

SUMMARY OF PRODUCT CHARACTERISTICS

Update on Rhopressa TM QD (netarsudil ophthalmic solution) 0.02% and Roclatan TM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.

A. Incorrect! Acetazolamide is a carbonic anhydrase inhibitor given orally or by intravenous injection.

Condition: Herpes Zoster Ophthalmicus (HZO)

PRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. MAXIDEX * (Dexamethasone 1 mg/ml), Eye Drops. dexamethasone is: Chemical Name:

When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily.

TIMALEN 0.5% eye drops

Dorzolamide 20 mg/ml Eye Drops, Solution

PAINFUL PAINLESS Contact lens user BOV

Transcription:

Ophthalmological preparations

Administration of eye preparations Preparations for the eye should be sterile when issued. Use of single-application containers is preferable; multiple-application preparations include antimicrobial preservatives and when used particular care should be taken to prevent contamination of the contents, including the avoidance of contact between the applicator and the eye or other surfaces. Eye drops are generally instilled into the lower conjunctival sac which is accessed by gently pulling down the lower eyelid to form a pocket into which one drop is instilled. The eye should be kept closed for as long as possible after application, preferably 1 2 minutes. A small amount of eye ointment is applied similarly; the ointment melts rapidly and blinking helps to spread it. When two different eye drops are required at the same time, dilution and overflow may occur when one immediately follows the other; an interval of 5 minutes should be allowed between the two applications. Systemic absorption, which may occur after topical application of eye drops, can be minimized by using the finger to compress the lacrimal sac at the medial canthus for at least one minute after instillation of the drops. This helps block the passage of the drops through the naso-lacrimal duct. PERFORMANCE OF SKILLED TASKS Application of eye preparations may cause blurring of vision which is generally transient; patients should be advised not to carry out skilled tasks such as operating machinery or driving until their vision has cleared. Anti-infective drugs Blepharitis, conjunctivitis, keratitis and endophthalmitis are common acute infections of the eye and can be treated topically. However, in some cases, for example, in gonococcal conjunctivitis, both topical and systemic anti-infective treatment may be necessary. Blepharitis and conjunctivitis are often caused by staphylococcus, while keratitis and endophthalmitis may be bacterial, viral or fungal. Bacterial blepharitis is treated with an antibacterial eye ointment or drops. Although most cases of acute bacterial conjunctivitis may resolve spontaneously, anti-infective treatment shortens the infectious process and prevents complications. Acute infective conjunctivitis is treated with antibacterial eye drops by day and eye ointment applied at night. A poor response may indicate viral or allergic conjunctivitis. Keratitis requires immediate specialist treatment. Gentamicin is a broad-spectrum bactericidal aminoglycoside antibiotic with particular activity against Pseudomonas aeruginosa, Neisseria gonorrhoea and other bacteria that may be implicated in blepharitis or conjunctivitis. Topical application may lead to systemic absorption and possible adverse effects.

Idoxuridine is an antiviral used in the treatment of keratitis due to herpes simplex virus. Idoxuridine is effective against epithelial infections of recent origin. These may respond to treatment within a week and resolve completely in 1 2 weeks. Eye drops must be applied frequently to maintain a high concentration and achieve a successful therapeutic outcome; however, if there is no relief within 7 days, treatment should be discontinued and alternative treatment is indicated. For systemic treatment with antivirals such as aciclovir, see section 6.5.1. Silver nitrate is a topical anti-infective. Its antibacterial activity is attributed to precipitation of bacterial proteins by silver ions. It is available in 1% ophthalmic solutions and is used for prophylaxis of gonococcal ophthalmia neonatorum. Tetracycline is a broad spectrum antibiotic with activity against many Gram-positive and Gram-negative bacteria including N. gonorrhoea, and most chlamydia, rickettsia, mycoplasma and spirochetes. Ophthalmic tetracycline is used in blepharitis, conjunctivitis, and keratitis produced by susceptible bacteria. Tetracycline is also used in the treatment of trachoma caused by Chlamydia trachomatis and in the prophylaxis of neonatal conjunctivitis (ophthalmia neonatorum) caused by N. gonorrhoea and C. trachomatis. Gentamicin Gentamicin is a representative antibacterial. Various drugs can serve as alternatives Eye drops, solution, gentamicin (as sulfate) 0.3% blepharitis; bacterial conjunctivitis; systemic infections (section 6.2.2.5) hypersensitivity to aminoglycoside group of antibiotics prolonged use may lead to skin sensitization and emergence of resistant organisms including fungi; discontinue if purulent discharge, inflammation or exacerbation of pain Mild to moderate infection, by instillation into the eye, ADULT and CHILD 1 drop every 2 hours, reducing frequency as infection is controlled, then continue for 48 hours after healing is complete Severe infection, by instillation into the eye, ADULT and CHILD 1 drop every hour, reducing frequency as infection is controlled, then continue for 48 hours after healing is complete

burning, stinging, itching, dermatitis Idoxuridine Idoxuridine is a representative antiviral. Various drugs can serve as alternatives Eye drops, solution, idoxuridine 0.1% Eye ointment, idoxuridine 0.2% keratitis or keratoconjunctivitis caused by herpes simplex pregnancy; concurrent use of an eye preparation containing boric acid existing deep ulceration of cornea; prolonged or excessive use may damage the cornea; do not exceed frequency or duration of treatment, discontinue if no relief within 7 days; concurrent use of a corticosteroid Herpes simplex keratitis, by instillation into the eye, ADULT and CHILD 1 drop every hour during daytime and every 2 hours at night-time, reducing frequency as infection is controlled to 1 drop every 2 hours during daytime and every 4 hours at night-time, then continue for 3 5 days after healing is complete; maximum length of treatment 21 days Herpes simplex keratitis, by application to the eye, ADULT and CHILD 1 application of ointment every 4 hours during daytime and once at night-time (5 applications), then continue for 3 5 days after healing is complete; maximum length of treatment 21 days occasionally burning, itching, irritation, pain, conjunctivitis, oedema, inflammation, photophobia, pruritus; rarely allergic reactions Silver nitrate Eye drops, solution, silver nitrate 1%

prophylaxis of neonatal conjunctivitis (ophthalmia neonatorum) due to Neisseria gonorrhoea, if tetracycline not available avoid use of old, concentrated drops; wipe excess drops from skin near the eye to prevent staining Prophylaxis of neonatal conjunctivitis, by instillation into the eye, NEWBORN at birth after cleansing eyes with sterile gauze, 2 drops into each eye skin and mucous membrane irritation; mild conjunctivitis; repeated use may cause skin discoloration, corneal cauterization and blindness Tetracycline hydrochloride Tetracycline is a representative antibacterial. Various drugs can serve as alternatives Eye ointment, tetracycline hydrochloride 1% superficial bacterial infection of the eye; mass treatment of trachoma in endemic areas; prophylaxis of neonatal conjunctivitis (ophthalmia neonatorum) due to Neisseria gonorrhoea or Chlamydia trachomatis hypersensitivity to tetracycline group of antibiotics prolonged use may lead to overgrowth of non-susceptible organisms Superficial bacterial infection, by application to the eye, ADULT and CHILD aged over 8 years 1 application of ointment 3 4 times daily Prophylaxis of neonatal conjunctivitis, by application to the eye, NEWBORN at birth after cleansing eyes with sterile gauze, 1 application of ointment into each eye; close eyelids and massage gently to aid spread of ointment Trachoma, intermittent treatment, by application to the eye, ADULT and CHILD 1 application of ointment into each eye either twice daily for 5 days or once daily for 10 days, every month for 6 consecutive months each year, repeated as necessary

Trachoma, continuous intensive treatment, by application to the eye, ADULT and CHILD 1 application of ointment into each eye twice daily for at least 6 weeks rash; rarely stinging, burning Anti-inflammatory drugs Ophthalmic corticosteroids should only be used under supervision of an ophthalmologist as inappropriate use is potentially blinding. Dangers include the development of open-angle glaucoma (chronic simple glaucoma) and cataracts, and the aggravation of a simple herpes simplex epithelial lesion into an extensive corneal ulcer and subsequent permanent corneal scarring, with possible damage to vision and even loss of the eye. Corticosteroids such as prednisolone are useful in the treatment of inflammatory conditions including uveitis and scleritis. They are also used for reducing postoperative ocular inflammation. Before administration of an ophthalmic corticosteroid, the possibility of bacterial, viral or fungal infection should be excluded. Treatment should be the lowest effective dose for the shortest possible time; if long-term therapy (more than 6 weeks) is unavoidable, withdrawal of an ophthalmic corticosteroid should be gradual to avoid relapse. Prednisolone sodium phosphate Prednisolone is a representative corticosteroid. Various drugs can serve as alternatives Eye drops, solution, prednisolone sodium phosphate 0.5% short-term local treatment of inflammation of the eye; malignant disease (section 8.3); inflammatory and allergic reactions (section 18.1, also section 3.1) undiagnosed red eye caused by herpetic keratitis; glaucoma cataract; corneal thinning, corneal or conjunctival infection; discontinue treatment if no improvement within 7 days; risk of adrenal suppression after prolonged use in infants NOTE. Use only under the supervision of an ophthalmologist

Inflammation of the eye, by instillation into the eye, ADULT and CHILD 1 drop every 1 2 hours, reducing frequency as inflammation is controlled secondary ocular infection; impaired corneal healing (due to corneal thinning), optic nerve damage, cataract; glaucoma, mydriasis, ptosis, epithelial punctate keratitis, delayed hypersensitivity reactions including burning, stinging Local anaesthetics Topical local anaesthetics are employed for simple ophthalmological procedures and for short operative procedures involving the cornea and conjunctiva. Tetracaine, available in 0.5% ophthalmic solution, provides a rapid local anaesthesia which lasts for 15 minutes or more. Prolonged or unsupervized use of tetracaine is not recommended. Tetracaine hydrochloride Amethocaine Tetracaine is a representative local anaesthetic. Various drugs can serve as alternatives Eye drops, solution, tetracaine hydrochloride 0.5% short-acting local anaesthesia of cornea and conjunctiva hypersensitivity to ester-type local anaesthetics; eye inflammation or infection avoid prolonged use (cause of severe keratitis, permanent corneal opacification, scarring, delayed corneal healing); protect eye from dust and bacterial contamination until sensation fully restored Local anaesthesia, by instillation into the eye, ADULT and CHILD 1 drop burning, stinging, redness; rarely, allergic reactions may occur

Antiglaucoma drugs Glaucoma is normally associated with raised intra-ocular pressure and eventual damage to the optic nerve which may result in blindness. The rise in pressure is almost always due to reduced outflow of aqueous humour, the inflow remaining constant. The most common condition is chronic open-angle glaucoma (chronic simple glaucoma) in which the intra-ocular pressure increases gradually and the condition is usually asymptomatic until well advanced. In contrast, angle-closure glaucoma (closed-angle glaucoma) usually occurs as an acute emergency resulting from a rapid rise in intra-ocular pressure; if treatment is delayed, chronic angleclosure glaucoma may develop. Ocular hypertension is a condition in which intraocular pressure is raised without signs of optic nerve damage. Drugs used in the treatment of glaucoma lower the intra-ocular pressure by a variety of mechanisms including reduction in secretion of aqueous humour by the ciliary body, or increasing the outflow of the aqueous humour by opening of the trabecular network. Antiglaucoma drugs used include topical application of a beta-blocker (betaadrenoceptor antagonist), a miotic, or a sympathomimetic such as epinephrine; systemic administration of a carbonic anhydrase inhibitor may be used as an adjunct. Timolol is a non-selective beta-blocker that reduces the secretion of aqueous humour. A beta-blocker is usually the drug of choice for initial and maintenance treatment of chronic open-angle glaucoma. If further reduction in intra-ocular pressure is required a miotic, a sympathomimetic or a systemic carbonic anhydrase inhibitor may be used with timolol. In angle-closure glaucoma, timolol should be used with a miotic and not alone. Since systemic absorption can occur, an ophthalmic betablocker should be used with caution in certain individuals. A miotic such as pilocarpine, through its parasympathomimetic action, contracts the iris sphincter muscle and the ciliary muscle, and opens the trabecular network. It is used in chronic open-angle glaucoma either alone or, if required, with a beta-blocker, epinephrine or a systemic carbonic anhydrase inhibitor. Pilocarpine is used with systemic acetazolamide in an acute attack of angle-closure glaucoma prior to surgery; however, it is not advisable to use pilocarpine after surgery because of a risk of posterior synechiae forming. Systemic absorption of topically applied pilocarpine can occur producing muscarinic adverse effects. The sympathomimetic drug epinephrine (adrenaline) probably acts by reducing the rate of production of aqueous humour and increasing the outflow through the trabecular network. Epinephrine is usually used with a miotic, a beta-blocker or a systemic carbonic anhydrase inhibitor in the treatment of chronic open-angle glaucoma; however, because epinephrine is also a mydriatic, it is contraindicated for angle-closure glaucoma unless an iridectomy has been carried out. Acetazolamide, by reducing carbonic anhydrase in the eye, reduces the production of aqueous humour and so reduces intra-ocular pressure. It is used systemically as an adjunct in chronic open-angle glaucoma unresponsive to treatment with topically applied antiglaucoma drugs. Prolonged therapy with acetazolamide is not normally recommended, but if treatment is unavoidable blood count and plasma electrolyte concentration should be monitored. Acetazolamide is also used as part of emergency

treatment for an acute attack of angle-closure glaucoma; however it should not be used in chronic angle-closure glaucoma as it may mask deterioration of the condition. Miotics Pilocarpine Pilocarpine is a representative miotic. Various drugs can serve as alternatives Eye drops, solution, pilocarpine hydrochloride 2%, 4%; pilocarpine nitrate 2%, 4% chronic open-angle glaucoma, ocular hypertension; emergency treatment of acute angle-closure glaucoma; to antagonize effects of mydriasis and cycloplegia following surgery or ophthalmoscopic examination acute iritis, acute uveitis, anterior uveitis, some forms of secondary glaucoma; acute inflammation of anterior segment; not advisable after angle-closure surgery (risk of posterior synechiae) retinal disease, conjunctival or corneal damage; monitor intra-ocular pressure in chronic open-angle glaucoma and in long-term treatment; cardiac disease, hypertension, asthma, peptic ulceration, urinary-tract obstruction, Parkinson disease; stop treatment if symptoms of systemic toxicity develop Skilled tasks. Causes difficulty with dark adaptation; may cause accommodation spasm. Do not carry out skilled tasks, for example operating machinery or driving until vision is clear Chronic open-angle glaucoma, by instillation into the eye, ADULT 1 drop (2% or 4%) up to 4 times daily Acute angle-closure glaucoma before surgery, by instillation into the eye, ADULT 1 drop (2%) every 10 minutes for 30 60 minutes, then 1 drop every 1 3 hours until intra-ocular pressure subsides eye pain, blurred vision, ciliary spasm, lacrimation, myopia, browache; conjunctival vascular congestion, superficial keratitis, vitreous haemorrhage and increased pupillary block have been reported; lens opacities have occurred following prolonged use; rarely systemic effects including hypertension, tachycardia, bronchial spasm, pulmonary oedema, salivation, sweating, nausea, vomiting, diarrhoea

Beta-blockers Timolol Timolol is a representative beta-blocker. Various drugs can serve as alternatives Eye drops, solution, timolol (as maleate) 0.25%, 0.5% ocular hypertension; chronic open-angle glaucoma, aphakic glaucoma, some secondary glaucomas uncontrolled heart failure, bradycardia, heart block; asthma, obstructive airways disease older people (risk of keratitis); if used in angle-closure glaucoma, use with a miotic, and not alone; interactions: Appendix 1 Ocular hypertension, chronic open-angle glaucoma, aphakic glaucoma, some secondary glaucomas, by instillation into the eye, ADULT 1 drop (0.25% or 0.5%) twice daily stinging, burning, pain, itching, erythema, transient dryness, allergic blepharitis, transient conjunctivitis, keratitis, decreased corneal sensitivity, diplopia, ptosis; systemic effects, particularly on the pulmonary, cardiovascular and central nervous systems, may follow absorption Sympathomimetics Epinephrine (adrenaline) Epinephrine is a complementary drug for use when drugs in the main list cannot be made available Eye drops, solution, epinephrine (as hydrochloride) 0.5%, 1% chronic open-angle glaucoma, ocular hypertension; anaphylaxis (section 3.1); cardiac arrest (section 12.2)

angle-closure glaucoma, unless an iridectomy has been carried out hypertension, heart disease, aneurysm, arrhythmia, tachycardia, hyperthyroidism, cerebral arteriosclerosis, diabetes mellitus Chronic open-angle glaucoma, by instillation into the eye, ADULT 1 drop (0.5% or 1%) 1 2 times daily stinging, blurred vision, photophobia, eye pain, conjunctival hyperaemia, headache or browache; occasionally, conjunctival sensitization and local skin reactions; after prolonged use conjunctival pigmentation and macular oedema in aphakia; systemic adverse reactions are rare following topical use at normal dosage but tachycardia, hypertension, arrhythmia, dizziness, sweating may occur Carbonic anhydrase inhibitors Acetazolamide Tablets, acetazolamide 250 mg as an adjunct in the treatment of chronic open-angle glaucoma; secondary glaucoma; as part of pre-operative treatment of acute angle-closure glaucoma hypersensitivity to sulfonamides; chronic angle-closure glaucoma (may mask deterioration); hypokalaemia, hyponatraemia, hyperchloraemic acidosis; renal impairment (Appendix 4), severe hepatic impairment elderly; pregnancy (Appendix 2); breastfeeding (Appendix 3); diabetes mellitus; pulmonary obstruction; monitor blood count and electrolytes if used for long periods; interactions: Appendix 1 Skilled tasks. May impair ability to perform skilled tasks, for example operating machinery, driving Dosage:

Chronic open-angle glaucoma, secondary glaucoma, by mouth, ADULT 0.25 1 g daily in divided doses nausea, vomiting, diarrhoea, taste disturbance; loss of appetite, paraesthesia, flushing, headache, dizziness, fatigue, irritability, depression; thirst, polyuria; reduced libido; metabolic acidosis and electrolyte disturbances on long-term therapy; occasionally drowsiness, confusion, hearing disturbances, urticaria, melaena, glycosuria, haematuria, abnormal liver function, renal calculi, blood disorders including agranulocytosis and thrombocytopenia, rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis; transient myopia reported Mydriatics and cycloplegics Antimuscarinics, by blocking the cholinergic effects of acetylcholine, paralyse the pupillary constrictor muscles causing dilation of the pupil (mydriasis) and paralyse the ciliary muscles resulting in paralysis of accommodation (cycloplegia). Mydriasis may precipitate acute angle-closure glaucoma particularly in elderly or long-sighted patients. In patients with dark iridic pigmentation, higher concentrations of mydriatic drugs are usually required and care should be taken to avoid overdosing. Atropine is a long-acting antimuscarinic used for cycloplegic refraction procedures, particularly in children. It is also used to immobilize the ciliary muscle and iris and to prevent formation of posterior synechiae in the treatment of inflammatory eye disorders such as iritis and uveitis. Atropine sulfate Eye drops, solution, atropine sulfate 0.1%, 0.5%, 1% iritis, uveitis; cycloplegic refraction procedures; premedication (section 1.3); organophosphate poisoning (section 4.2.3); antispasmodic (section 17.5) angle-closure glaucoma may precipitate acute attack of angle-closure glaucoma, particularly in the elderly or long-sighted; risk of systemic effects with eye drops in infants under 3 months eye ointment preferred Skilled tasks. May cause sensitivity to light and blurred vision. Do not carry out skilled tasks, for example operating machinery or driving, until vision is clear

Cycloplegic refraction, by instillation into the eye, ADULT 1 drop (1%) twice daily for 1 2 days before procedure or a single application of 1 drop (1%) 1 hour before procedure; CHILD under 3 months (see Precautions), 3 months 1 year (0.1%), 1 5 years (0.1 0.5%), over 5 years (0.5 1%), 1 drop twice daily for 1 3 days before procedure with a further dose given 1 hour before procedure Iritis, uveitis, by instillation into the eye, ADULT 1 drop (0.5 or 1%) up to 4 times daily; CHILD 1 drop (0.5 or 1%) up to 3 times daily transient stinging and raised intra-ocular pressure; on prolonged administration, local irritation, hyperaemia, oedema and conjunctivitis may occur; contact dermatitis; systemic toxicity may occur in the very young and the elderly